Membrane bound IL-21 based NK cell feeder cells drive robust
2019年10月17日 · We created an NK cell feeder cell line termed ‘NKF’ through overexpressing membrane bound IL-21 that is capable of inducing robust and sustained proliferation (>10,000-fold expansion at 5 weeks)...
Membrane-bound IL-21 promotes sustained ex vivo proliferation ... - PubMed
We developed K562-based aAPCs with membrane-bound IL-21 (mbIL21) and assessed their ability to support human NK-cell proliferation. In contrast to mbIL15, mbIL21-expressing aAPCs promoted log-phase NK cell expansion without evidence of senescence for up to 6 …
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor ... - PubMed
2017年10月19日 · To test the hypothesis that natural killer (NK) cells can decrease the risk of leukemia relapse, we initiated a phase 1 dose-escalation study of membrane-bound interleukin 21 (mbIL21) expanded donor NK cells infused before and after haploidentical HSCT for high-risk myeloid malignancies.
Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express ...
In this chapter, a robust NK cell expansion protocol is described using K562 cell line gene modified to express membrane bound IL21 (K562 mb.IL21).
Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo ...
2017年12月8日 · The aim was to determine the maximum tolerated dose of ex vivo expanded NK cells with a K562 expressing mb-IL21 feeder cell system in patients with myeloid malignancies (AML/MDs/CML). Patients received conditioning with melphalan 140mg/m2, fludarabine 160mg/m2 and 2GyTBI, and GVHD prophylaxis with post …
Interim Results of a Phase 2 Clinical Trial Using Mb-IL21
2017年12月7日 · The aim was to determine the maximum tolerated dose of ex vivo expanded NK cells with a K562 expressing mb-IL21 feeder cell system in patients with myeloid malignancies (AML/MDs/CML). Patients received conditioning with melphalan 140mg/m 2 , fludarabine 160mg/m 2 and 2GyTBI, and GVHD prophylaxis with …
Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized ...
2017年9月21日 · Our findings demonstrate that ex vivo NK cell expansion with K562-mb-IL-21 cells is promising for adoptive NK cell therapy, as it generates expanded, functional NK cells that can survive and ...
Decrease post-transplant relapse using donor-derived expanded …
2021年7月26日 · In this phase I/II clinical trial, we investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid...
K562-mbIL21 (h)·myc-BSD稳转株-镇江维根生物科技有限公司
过表达膜定位人 IL21 基因的 K562 稳转株. Lot number. K562-34H7P. 细胞规格. 复苏细胞 (T25细胞瓶) 或1 × 10 6 细胞冻存细胞. 细胞形态. 淋巴母细胞样. 生长特性. 悬浮生长. 细胞株. 构建流程 （1）构建目的基因过表达慢病毒重组质粒，并包装慢病毒； （2）慢病毒以合适的 ...
具有膜结合型IL-21的免疫细胞及其制法和应用.pdf-原创力文档
2024年3月6日 · 具体地，本发明公开了一种膜结合型IL‑21 (membrane‑boundIL‑21,mbIL‑21)及其在免疫疗法中的应用。 本发明的mbIL‑21可以增强特定免疫细胞的扩增能力和杀伤力，从而增强NK细胞疗法效果。 胞及其制法和应用。 具体地，本发明公开了一种. 21)及其在免疫疗法中的应用。 本发明的mbIL‑21. 而增强NK细胞疗法效果。 1.一种重组蛋白，其特征在于，所述重组蛋白为膜结合型IL‑21 (mbIL‑21)。 “‑”为肽键或连接肽。 序列。 4.一种分离的多核苷酸，其特征在于， …